Effect of a single dose of 8 mg moxidectin or 150 [mu]g/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection

Our study in CDTI-naïve areas in Nord Kivu and Ituri (Democratic Republic of the Congo, DRC), Lofa County (Liberia) and Nkwanta district (Ghana) showed that a single 8 mg moxidectin dose reduced skin microfilariae density (microfilariae/mg skin, SmfD) better and for longer than a single 150[mu]g/kg...

Full description

Saved in:
Bibliographic Details
Published in:PLoS Neglected Tropical Diseases 2022, Vol.16 (4)
Main Authors: Bakajika, Didier, Kanza, Eric M, Opoku, Nicholas O, Howard, Hayford M, Mambandu, Germain L, Nyathirombo, Amos, Nigo, Maurice M, Kennedy, Kambale Kasonia, Masembe, Safari L, Mumbere, Mupenzi, Kataliko, Kambale, Bolay, Kpehe M, Attah, Simon K, Olipoh, George, Asare, Sampson, Vaillant, Michel, Halleux, Christine M, Kuesel, Annette C
Format: Report
Language:English
Subjects:
Care and treatment
Diagnosis
Dosage and administration
Ivermectin
Onchocerciasis
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our study in CDTI-naïve areas in Nord Kivu and Ituri (Democratic Republic of the Congo, DRC), Lofa County (Liberia) and Nkwanta district (Ghana) showed that a single 8 mg moxidectin dose reduced skin microfilariae density (microfilariae/mg skin, SmfD) better and for longer than a single 150[mu]g/kg ivermectin dose. We now analysed efficacy by study area and pre-treatment SmfD (intensity of infection, IoI). Four and three IoI categories were defined for across-study and by-study area analyses, respectively. We used a general linear model to analyse SmfD 1, 6, 12 and 18 months post-treatment, a logistic model to determine the odds of undetectable SmfD from month 1 to month 6 (UD1-6), month 12 (UD1-12) and month 18 (UD1-18), and descriptive statistics to quantitate inter-interindividual response differences. Twelve months post-treatment, treatment differences (difference in adjusted geometric mean SmfD after moxidectin and ivermectin in percentage of the adjusted geometric mean SmfD after ivermectin treatment) were 92.9%, 90.1%, 86.8% and 84.5% in Nord Kivu, Ituri, Lofa and Nkwanta, and 74.1%, 84.2%, 90.0% and 95.4% for participants with SmfD 10-20, [greater than or equal to]20-
ISSN:1935-2727
DOI:10.1371/journal.pntd.0010079